MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma

By F. Fornari, L. Gramantieri, M. Ferracin, A. Veronese, S. Sabbioni, G. Calin, G. Grazi, C. Giovannini, C. Croce, L. Bolondi and 1 more. Oncogene, 2008

665 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/2c66cb1e156aa004ec9a17b87d1aa939f65bd33c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Gianpiero di Leva
2. Danish H Sayed
3. M. Abdellatif
4. M. Garofalo
5. Carlo Maria Croce
6. George A. Calin
7. Marilena V. Iorio
8. Manel Esteller

In Molecular Biology

1. Gianpiero di Leva
2. Danish H Sayed
3. M. Abdellatif
4. M. Garofalo
5. Carlo Maria Croce
6. George A. Calin
7. Marilena V. Iorio
8. Manel Esteller

Citations in the corpus

• microRNAs in cancer (2013, background): “Expression of miR-222/221 is highly upregulated in a variety of solid tumors and cancer cell lines, including hepatocarcinoma (135), estrogen receptor– negative breast cancer cells (136), thyroid cancer (137), and melanoma cells (138).”
• MicroRNAs in development and disease. (2011, background): “Other miRNAs with oncogenic functions (oncomirs) in HCC include the following: miR21, which suppresses PTEN and is associated with an increase in phospho-AKT, phospho-focal adhesion kinase (pFAK), and metalloproteinase 2 (MMP2) (417); miR-221, which inhibits the cell cycle inhibitors p27 and p57 (18”
• Causes and consequences of microRNA dysregulation in cancer (2009, neutral): “, papillary thyroid carcinoma, hepatocellular carcinom”